GOLDMAN SACHS GROUP INC - XERIS BIOPHARMA HOLDINGS INC ownership

XERIS BIOPHARMA HOLDINGS INC's ticker is and the CUSIP is 98422E103. A total of 104 filers reported holding XERIS BIOPHARMA HOLDINGS INC in Q2 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of XERIS BIOPHARMA HOLDINGS INC
ValueSharesWeighting
Q3 2023$247,082
-57.9%
132,840
-40.7%
0.00%
Q2 2023$587,252
+189.3%
224,142
+80.0%
0.00%
Q1 2023$203,025
-6.8%
124,555
-24.0%
0.00%
Q4 2022$217,908
+14.1%
163,840
+33.6%
0.00%
Q3 2022$191,000
+10.4%
122,646
+9.0%
0.00%
Q2 2022$173,000
-90.7%
112,540
-84.5%
0.00%
Q1 2022$1,857,000
+178.4%
725,255
+218.5%
0.00%
Q4 2021$667,000227,6910.00%
Other shareholders
XERIS BIOPHARMA HOLDINGS INC shareholders Q2 2022
NameSharesValueWeighting ↓
CAXTON CORP 6,039,028$9,843,61624.86%
Stonepine Capital Management, LLC 8,640,205$14,083,5344.72%
Alpine Global Management, LLC 400,000$652,0000.25%
DELTEC ASSET MANAGEMENT LLC 622,072$1,013,9770.25%
XTX Topco Ltd 233,385$380,4180.08%
Redmile Group, LLC 1,046,587$1,705,9370.07%
GSA CAPITAL PARTNERS LLP 316,025$5150.05%
Yakira Capital Management, Inc. 90,076$146,8240.04%
IHT Wealth Management, LLC 281,442$458,7620.03%
TUDOR INVESTMENT CORP ET AL 960,111$1,5650.02%
View complete list of XERIS BIOPHARMA HOLDINGS INC shareholders